Back to Journals » OncoTargets and Therapy » Volume 6

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

Authors Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA

Received 18 January 2013

Accepted for publication 20 March 2013

Published 10 May 2013 Volume 2013:6 Pages 531—538

DOI https://doi.org/10.2147/OTT.S34498

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4


Evangelos Terpos, Nikolaos Kanellias, Dimitrios Christoulas, Efstathios Kastritis, Meletios A Dimopoulos

Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra University Hospital, Athens, Greece


Abstract: Multiple myeloma remains an incurable disease despite the introduction of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib that have improved the outcome of patients with both newly diagnosed and relapsed/refractory disease. However, patients who relapse after treatment with these agents or are refractory to them represent an unmet need and highlight the necessity for the development of novel anti-myeloma agents. Pomalidomide is an IMiD, structurally related to thalidomide, with enhanced antiangiogenic, antineoplastic, and anti-inflammatory properties and exhibiting potent anti-myeloma activity in vitro and in vivo. Pomalidomide has shown remarkable activity in patients who were refractory to both bortezomib and lenalidomide in Phase II and III studies. This paper reviews the chemistry and mechanisms of action of pomalidomide as well as all the available data from clinical trials on pomalidomide use in patients with refractory/relapsed multiple myeloma.

Keywords: immunomodulatory drugs, cereblon, angiogenesis, lenalidomide, refractory

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]